Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules

Journal of Materials Science: Materials in Medicine

Volumn 25, Issue 10, 2014, Pages 2373-2381

  Pascaud, P ^a   Errassifi, F ^a   Brouillet, F ^a   Sarda, S ^a   Barroug, A ^b   Legrouri, A ^c   Rey, C ^a  

^a CNRS   (France)

^b FACULTÉ DES SCIENCES SEMLALIA   (Morocco)

^c AL AKHAWAYN UNIVERSITY   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORPTION; APATITE; BONE; CALCIUM PHOSPHATE; HYDROXYAPATITE; ION EXCHANGE; MOLECULES; NANOCRYSTALLINE MATERIALS; NANOCRYSTALS; PHOSPHATES; TARGETED DRUG DELIVERY;

ADSORPTION PROPERTIES; APATITIC CALCIUM PHOSPHATES; ION EXCHANGE REACTIONS; NANOCRYSTALLINE APATITES; PHYSICOCHEMICAL CONDITIONS; PHYSICOCHEMICAL PARAMETERS; STRUCTURAL CHARACTERISTICS; SURFACE CHARACTERISTICS;

CONTROLLED DRUG DELIVERY;

APATITE; CALCIUM PHOSPHATE; HYDROXYAPATITE; NANOCRYSTAL; RISEDRONIC ACID; TILUDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION; ETIDRONIC ACID;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ION EXCHANGE; PH; PHYSICAL CHEMISTRY; SURFACE PROPERTY; TEMPERATURE; ADSORPTION; ANALOGS AND DERIVATIVES; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG INTERACTION; TIME;

ADSORPTION; APATITES; CALCIUM PHOSPHATES; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; ETIDRONIC ACID; TIME FACTORS;

EID: 84918811571     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-014-5218-0     Document Type: Article

References (40)

1. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692.
2. Russell RGG, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–59.
3. Nancollas GH, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617–27.
4. Mönkkönen J, Similä J, Rogers MJ. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci. 1998;62(8):PL95–PL102.
5. Elliott SN, et al. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci. 1997;62(1):77–91.
6. Demerjian N, Bolla G, Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol. 1999;18(4):349–50.
7. Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation. Biosci Hypotheses. 2009;2(1):34–6.
8. Hoffman A, et al. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm. 2001;220(1–2):1–11.
9. Denissen H, et al. Ceramic hydroxyapatite implants for the release of bisphosphonate. Bone and Miner. 1994;25(2):123–34.
10. Josse S, et al. Novel biomaterials for bisphosphonate delivery. Biomaterials. 2005;26(14):2073–80.
11. Panzavolta S, et al. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem. 2009;103(1):101–6.
12. Errassifi F, et al. Adsorption on apatitic calcium phosphates: application to drug delivery. In: Soc AC, Editor. 8th Pacific rim conference on ceramic and glass technology. Vancouver; 2010. p. 159–174.
13. Pascaud P, et al. Interaction between a bisphosphonate, tiludronate, and biomimetic nanocrystalline apatites. Langmuir. 2013;29:2224–32.
14. Palazzo B, et al. Biomimetic Hydroxyapatite-Drug Nanocrystals as Potential Bone Substitutes with Antitumor Drug Delivery Properties. Adv Func Mater. 2007;17(13):2180–8.
15. Rey C, et al. Nanocrystalline apatites in biological systems: characterisation, structure and properties. Materialwiss Werkstofftech. 2007;38(12):996–1002.
16. Eichert D, et al. Nanocrystalline apatite-based biomaterials: synthesis, processing and characterization. Biomater Res Adv. 2008. 93.
17. Trombe JC. Contribution à l’étude de la décomposition et la réactivité de certaines apatites hydroxylées carbonatées ou fluorées alcalino-terreuses. 1972. Toulouse: UPS.
18. Rey C, et al. Maturation of poorly crystalline apatites: chemical and structural aspects in vivo and in vitro. Cells Mater. 1995;5(4):345–56.
19. Charlot G. Chimie analytique quantitative. Masson et Cie ed: Paris; 1974.
20. Europe Co. (Editor). European Pharmacopoeia 7th ed. Strasbourg: 2011.
21. Al-Kattan A, et al. Medical potentialities of biomimetic apatites through adsorption, ionic substitution, and mineral/organic associations: three illustrative examples. Adv Eng Mater. 2010;12(7):B224–33.
22. Errassifi F. Mécanismes d’adsorption du risédronate par des phosphates de calcium biologiques: applications aux biomatériaux. Cadi Ayyad University: Marrakech; 2011. p. 239.
23. Pascaud P, et al. Interaction between a bisphosphonate, tiludronate and nanocrystalline apatite: in vitro viability and proliferation of HOP and HBMSC cells. Biomed Mater. 2012;7(5):1–9.
24. Gómez-Morales J, et al. Progress on the preparation of nanocrystalline apatites and surface characterization: overview of fundamental and applied aspects. Prog Cryst Growth Charact Mater. 2013;59(1):1–46.
25. Benaziz L, et al. Adsorption of O-phospho-l-serine and l-serine onto poorly crystalline apatite. J Colloid Interface Sci. 2001;238(1):48–53.
26. Ouizat S, et al. Adsorption of bovine serum albumin on poorly crystalline apatite: influence of maturation. Mater Res Bull. 1999;34(14–15):2279–89.
27. Barroug A, et al. Adsorption of catalase on hydroxyapatite. J Colloid Interface Sci. 1998;208(1):147–52.
28. Gorbunoff MJ. The interaction of proteins with hydroxyapatite: II. Role of acidic and basic groups. Anal Biochem. 1984;136(2):433–9.
29. Barroug A, et al. Interactions of cisplatin with calcium phosphate nanoparticles: in vitro controlled adsorption and release. J Orthop Res. 2004;22(4):703–8.
30. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973;11(4):269–80.
31. Yin G, et al. Impacts of the surface charge property on protein adsorption on hydroxyapatite. Chem Eng J. 2002;87(2):181–6.
32. López-Macipe A, et al. The role of pH in the adsorption of citrate ions on hydroxyapatite. J Colloid Interface Sci. 1998;200(1):114–20.
33. Errassifi F, et al. Infrared, Raman and NMR investigations of risedronate adsorption on nanocrystalline apatites. J Colloid Interface Sci. 2014;420:101–11.
34. Cukrowski I, et al. Modeling and spectroscopic studies of bisphosphonate-bone interactions. The Raman, NMR and crystallographic investigations of Ca-HEDP complexes. Bone. 2007;41(4):668–78.
35. Midy V, et al. Adsorption of vascular endothelial growth factor to two different apatitic materials and its release. J Mater Sci Mater Med. 2001;12(4):293–8.
36. Liu Y, et al. The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration. Biomaterials. 2007;28(16):2677–86.
37. Autefage H, et al. Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated hydroxyapatite/β-tricalcium phosphate porous ceramics. J Biomed Mater Res B Appl Biomater. 2009;91B(2):706–15.
38. Lebugle A, et al. Study of implantable calcium phosphate systems for the slow release of methotrexate. Biomaterials. 2002;23(16):3517–22.
39. Misra DN. Interaction of some alkali metal citrates with hydroxyapatite: ion-exchange adsorption and role of charge balance. Colloids Surf A. 1998;141(2):173–9.
40. Iafisco M, et al. Adsorption and conformational change of myoglobin on biomimetic hydroxyapatite nanocrystals functionalized with alendronate. Langmuir. 2008;24(9):4924–30.